Adverse events associated with Tezepelumab: a safety analysis of clinical trials and a pharmacovigilance system

Tezepelumab is the first asthma biologic approved by the FDA that is not restricted by biomarker phenotypes. To date, there have been no studies reporting adverse events (AEs) associated with the real-world use of tezepelumab.